Clinical trials: Oral Phase
Cognitive Disorders
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects
- Trial name
- NCT02881294
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Rotavirus Gastroenteritis
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks.
- Trial name
- NCT06967272
- Testing
- Oral hexavalent reassortant rotavirus attenuated live vaccine, Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Enteric Hyperoxaluria
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients with Enteric Hyperoxaluria (EH).
- Trial name
- NCT07871669
- Testing
- TRA16
- Volunteers
- 30 people
- Sponsor
- Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.
Infection, Human Immunodeficiency Virus
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT02738931
- Testing
- Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cancer
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
A multicenter, non-randomized, placebo-controlled, single dosing schedule, subject-blinded study to evaluate the effect of GSK1120212 on the electrical activity of the heart as compared to placebo in subjects with solid tumor…
- Trial name
- NCT01658553
- Testing
- GSK1120212
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).
- Trial name
- NCT05225805
- Testing
- Lefamulin
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nabriva Therapeutics AG
Healthy
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
This 2-part study will assess the effect of formulation and food on the pharmacokinetics of Indoximod in healthy volunteers. Part 1 is an open-label, 3-period, 6-sequence study.
- Trial name
- NCT03372239
- Testing
- Indoximod base formulation, Indoximod HCL (salt) formulation
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NewLink Genetics Corporation
Healthy Participants
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants
- Trial name
- NCT06568458
- Testing
- Nintedanib, BMS 986278
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Thrombocytopenic Purpura
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Core study: To compare the efficacy of avatrombopag (in addition to standard) of care to eltrombopag (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic…
- Trial name
- NCT01433978
- Testing
- Eltrombopag, Avatrombopag, Standard of care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Hypertension
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-341
- Trial name
- CKD-341 (NCT05921435)
- Testing
- CKD-341, D958
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Solid Tumours
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT…
- Trial name
- NCT01921140
- Testing
- Olaparib tablets, Pharmacokinetic sampling, Dietary Fasted
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
MSC2015103B in Solid Tumors
The main purpose of this study is to test the experimental drug, MSC2015103B at different dose levels and on different treatment schedules, to see whether it is safe and can be tolerated when given to subjects once a day one day…
- Trial name
- NCT01453387
- Testing
- MSC2015103B
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Healthy
Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects
The primary objective of the current study is to investigate the safety with special emphasis on ECG effects, and tolerability of dextromethorphan hydrobromide monohydrate (2mg/mL syrup) in healthy male and female subjects…
- Trial name
- NCT02191176
- Testing
- Dextromethorphan syrup - low dose, Dextromethorphan syrup - high dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Oral Mucositis
Study for the Prevention of Oral Mucositis (SPOM)
1. Study Design Prospective, Randomized, Questionnaire-Based Study Study Type: Phase 1/Phase 2 Interventional Clinical Trial Intervention Model: Parallel Assignment Masking: None (Open-label) Actual Enrollment: 100 participants…
- Trial name
- SPOM (NCT05338398)
- Testing
- Bocaliner, Benzydamine
- Where
- Armenia
- Volunteers
- 100 people
- Sponsor
- E2Bio Life Sciences, LLC
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01199315
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Acute Pain
Paracetamol UNIFLASH for Buccal Use Phase III Trial in Acute Pain Due to a Tooth Extraction
This study aims to evaluate the analgesic efficacy of single dose of a new paracetamol formulation (paracetamol UNIFLASH) for buccal use in comparison to two different doses of an oral paracetamol form controlled versus placebo.
- Trial name
- NCT04640376
- Testing
- Paracetamol Uniflash 125mg, Panadol 500 MG Oral Tablet X1, Panadol 500 MG Oral Tablet X2
- Where
- 20 sites in France, Italy and 2 more
- Volunteers
- 407 people
- Sponsor
- Unither Pharmaceuticals, France
Healthy Volunteer
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants
This randomized, double-blind, placebo-controlled, single ascending dose study will assess the safety, pharmacokinetics, and pharmacodynamics of RO6864018 in healthy, male, Asian and Caucasian participants.
- Trial name
- NCT02015715
- Testing
- RO6864018
- Where
- 2 sites in Singapore
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.